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Abstract Study was undertaken to identify patterns of
antidiabetic drugs prescribing in established type 2 diabetes
mellitus. Patients with established T2DM who attended the
endocrinology Outpatient Clinic in Postgraduate Institute of
Medical Education and Research, Chandigarh, India were
evaluated for social, demographical and clinical variables
and medications. 1185 established T2DM patients were
assessed. Metformin was the most commonly prescribed
drug [827 (70 %)], followed by insulin [627 (53 %)], sulfo-
nylureas [520 (44 %)], and pioglitazone [329 (28 %)]. The
most frequently prescribed monotherapy was insulin [214
(62 %)], followed by metformin in 81 (23 %), sulfonylurea
in 49 (14 %) and pioglitazone in 4 (1 %) patients. 704
(59 %) treated patients had uncontrolled hyperglycemia.
Family history (OR 1.76, 95%CI 1.18, 2.64), diabetes du-
ration (OR 2.62, 95 % CI 2.05, 3.36), HbA1c (OR 1.25,
95%CI 1.01, 1.50), neuropathy(OR 1.57, 95 % CI, 1.14,
2.2), nephropathy(OR 1.77, 95 % CI 1.40, 2.24), retinopa-
thy (OR 1.97, 95 % CI 1.63, 2.40), coronary arterial disease
(CAD) (OR 1.57, 95 % CI, 1.14, 2.2) and diabetic foot (OR
1.62, 95 % CI 1.12, 2.40) were all significantly associated
with insulin therapy. Obese and overweight patients were
prescribed oral antidiabetic drugs. Medication use was con-
sistent with practice guidelines in T2DM, even though the
outcome did not reach the goal.
Keywords Antidiabetic drug . Glycemic control . Tertiary
care hospital . T2DM . India
Introduction
Diabetes mellitus is a chronic incurable disease with rising
prevalence. Much of the burden of diabetes is due to the
development of vascular complications [1]. Type 2 Diabetes
Mellitus (T2DM) is a progressive disorder that is difficult to
treat effectively over the long term [2]. It is also associated
with other risk factors such as hypertension, adverse lipid
profiles and obesity. Even after correcting these risk factors,
CVD rates are still higher in patients with diabetes, implying
that hyperglycemia per se may amplify the underlying risk
of CVD. Optimal control of elevated blood glucose levels
will reduce the symptoms of hyperglycemia and help to
prevent the development of complications. Interventional
studies have established chronic high blood glucose level
as a cardiovascular disease (CVD) risk factor [3, 4].
Landmark trials have demonstrated that, intensive drug
therapy can improve glycemic control, reduce risk of mi-
crovascular and other diabetes related complications [5–8].
Antidiabetic drugs play a major role not only in control of
blood glucose but also in prevention or reduction of meta-
bolic and cardiovascular risk associated with the disease.
The current treatment goals focus on adequate and ag-
gressive treatment of blood glucose, blood pressure and
cholesterol levels. Several guidelines [American Diabetes
Association (ADA) [9], National Institute of Clinical
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Excellence (NICE) [10] and Indian Diabetes Management
[11]] recommend aggressive management to avoid compli-
cations. Despite these guidelines, treatment gaps exist,
whereby the actual patterns of practice do not meet clinical
practice guideline recommendations. It is recognized that
new guidelines or insights are not always implemented in
daily practice [12, 13]. Studies are scanty in South Asian
regions regarding practioners’ choices of antidiabetic thera-
pies for patients with established T2DM. The aims of this
study were to identify patterns of antidiabetic drug prescrib-
ing in established type 2 diabetes mellitus patients and to
evaluate determinants of the choice of antidiabetic therapy.
Patients and methods
This cross-sectional study was carried out from June
2007 to March 2009 at the Nehru Hospital, Postgradu-
ate Institute of Medical Education and Research, Chan-
digarh. Consecutive patients with T2DM, who attended
the Endocrinology Outpatient Clinic in Nehru hospital,
were evaluated. We included those patients who were
diagnosed to have T2DM at least 6 months earlier and
were on stable dose of antidiabetic drugs for the past
3 months. We excluded pregnant and lactating women
as well as patients with type 1 diabetes. The study
protocol was approved by the Institute’s Ethics Commit-
tee. Informed and written consent was obtained from all
the participants. The subjects were evaluated for social,
demographical and clinical variables and medications.
Anthropometric characteristics Standing body height (to
the nearest 0.5 cm) was measured with a commercial
stadiometer. A digital scale, with an accuracy of ±100 g,
was used to measure body weight (BW). The waist circum-
ference (WC) was measured in a horizontal plane, midway
between the inferior margin of the ribs and the superior
border of the iliac crest. Hip circumference (HC) was mea-
sured at the fullest point around the buttocks with a metallic
tape. The measurements were taken thrice and the mean was
taken in all cases. WC (cm) was divided by HC (cm) to
calculate waist to hip ratio (WHR). Body mass index (BMI)
(kg/m2) was calculated by dividing weight (in kilograms) by
the square of height (in meters), as a measure of total
adiposity. Systolic and diastolic blood pressure (SBP &
DBP) were measured twice at an interval of 3 min in the
sitting position after a 15 min rest, and the mean was taken
using Blood Pressure Instrument Table Model. Percent body
fat (%BF) was evaluated by impedance plethysmography
bioelectrical impedance meter (Omron BF 302, Tokyo).
Biochemical and clinical parameters Blood samples (3 ml)
were drawn after 8-12hr overnight fasting for themeasurement
of lipid profile [total cholesterol, high density lipoprotein
(HDL) cholesterol, and triglycerides] and fasting plasma glu-
cose levels. Plasma glucose was measured using the glucose
oxidaseperoxidase method [14], serum total cholesterol [15]
and triglycerides [16] by standard enzymatic procedures and
HDL cholesterol by direct assay method.
We also assessed both microvasular complications (neu-
ropathy, nephropathy retinopathy) and macrovascular com-
plications (coronary heart disease, cerebrovascular disease,
peripheral vascular disease). Neuropathy was evaluated by
history of numbness, paraesthesias, tingling sensation, burn-
ing sensation and it was confirmed by touch sensation using
10 g monofilament, vibration sense by biothesiometer
Vibrometer-VPT® (Diabetic Foot Care, Madras Engineering
Service, India) (VPT at great toe >25 mV were considered
significant) and ankle reflex. Incipient nephropathy was
diagnosed by Micral test and it was presumed to be
present if any two readings out of three of urinary
albumin and creatinine ratio were ranging from 30 μg/mg
to 300 μg/mg. Clinical nephropathy was evaluated by the
estimation of 24 h urine protein more than 500 mg/total
volume of urine. Ophthalmologist diagnosed retinopathy
by detailed fundus examination and was classified
according to Diabetic Retinopathy Study (DRS) and Ear-
ly Treatment Diabetic Retinopathy Study (ETDRS) [17].
Coronary artery disease was diagnosed by history of angina
or myocardial infarction or documented by previous treat-
ment records. Interpretation of ECG was recorded as per
Minnesota codes. Pathological Q wave (major Q wave ab-
normalities) in an ECG recording (Minnesota codes 1.1.1–
1.2.7), ST segment depression (codes 4.1–4.2), T wave ab-
normalities (codes 5.1–5.4) and chest x-ray was done to
assess cardiac size. Peripheral vascular disease (PVD)
was diagnosed by history of intermittent claudication or if
one or more peripheral pulses were absent in both feet. The
grading was done according to ankle brachial pressure index
(ABPI) by Doppler Study [Multi Duplex(R)-II (Huntleigh
Diagnostics—UK)]. PVD was diagnosed when ankle bra-
chial index was less than 0.9.
Drugs were grouped in four major classes of monotherapy-
insulin, metformin, sulphonylureas, and thiazolidinedione.
Combination therapy was analyzed separately. Monotherapy
was defined as a prescription for one agent. Combination
therapy was defined as a prescription for more than one agent
from two classes. Uncontrolled hyperglycemia was defined as
HbA1c (Glycosylated heamoglobin A1c) >7 % or FPG
(Fasting Plasma Glucose) >110 mg/dl or PPG (Post Prandial
Glucose) >140 mg/dl.
Statistical analysis
Results are reported as mean±SD or percentages, if not
indicated otherwise. Differences in characteristics between
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T2DM patients were tested with independent t tests for
normal distributed variables, with the Wilcoxon rank sum
test for skewed variables, and with the chi-square test for
categorical variables. Data were validated after double entry.
Logistic regression was used to find determinants for pre-
scribing of particular drug. Possible determinants were tak-
en as per recommendation in guidelines such as age, body
mass index, fasting and post prandial glucose level, lipid
levels, serum creatinine level, etcetera. Results are
expressed as Odds Ratio (OR) at 95 % confidence intervals
(CI). All statistical analyses were carried out using sigma
stat (Version 2.03, USA).
Results
1185 T2DM [606 (51 %) male and 579 (49 %) female]
patients were assessed. The mean (SD) age of patients was
55 (10) years. Patients had a mean duration of diagnosed
diabetes (SD) of 10 (7) years. The characteristics of the
T2DM patients are shown in Table 1.
Patterns of use of anti-diabetic drugs is shown in Table 2.
Metformin was the most commonly prescribed antidiabetic drug
[827 (70 %)] in general, followed by insulin [627 (53 %)],
sulfonylureas [520 (44 %)], and thiazolidinedione [329
(28 %)]. Metformin was mainly used from biguanides and
pioglitazone was mainly prescribed from thiazolidinedione.
None of the patients was on alpha-glucosidase inhibitors.
Among the 1185 patients, 348 (29 %) patients received
monotherapy and 837 (71 %) combination therapy. 570
(48 %) patients were on two drug combinations and 267
(22 %) on three or more . Among the monotherapy insulin
was the most frequently prescribed drug [214 (62 %)],
followed by metformin in 81 (23 %), sulfonylurea in 49
(14 %) and thiazolidinedione in 4 (1 %) patients. In the
combination drug therapy, oral antidiabetic drug (OAD)
combination was prescribed in 428 (36 %) patients and
insulin-OAD combination in 409 (34 %) patients. 277
(65 %) patients received a combination of OADs metfor-
min and sulfonylureas while 183 (45 %) patients received a
combination of insulin and metformin.
The utilization of diabetes medication in controlled and
uncontrolled hyperglycemic patients is in Table 3. 481
(41 % ) patients had controlled hyperglycemia. 704 (59 %)
treated patients had uncontrolled hyperglycemia. Among the
patients with uncontrolled hyperglycemia, the monotherapy
drug was prescribed in 239 (34 %), and the combination
therapy was in 465 (66 %) patients. Insulin as a
monotherapy was prescribed in 145 (61 %) patients, and
as a combination with metformin was in 114 (46 %) pa-
tients. Among the OADs the highly prescribed combination
was metformin and sulfonylureas 134 (62 %).
The utilization of diabetes medication in T2DM pa-
tients with complications is shown in Table 3. In pa-
tients with microvascular complications [936 (79 %)],
the monotherapy prescribed was in 287 (31 %) while
combination drug therapy was prescribed in 649 (69 %).
Insulin was the most commonly prescribed monotherapy
[176 (61 %)] in patients with microvascular complica-
tions. The most commonly prescribed OADs combina-
tion in patients with microvascular complication was
metformin and sulfonylureas 207 (66 %). Insulin and
metformin combination was prescribed in 151 (45 %)
patients.
Table 1 Differentiating characteristics of the established T2DM patients
Characteristics All (N=1185) Male (N=606) Female (N=579) P value
Age (Yrs) 55.4±10.4 56.7±10.4 54.6±10 <0.001
BMI (Kg/m2) 26.2±4.7 25.3±11.8 27.3±5.2 <0.001
Duration of DM (Yrs) 9.6±7.4 10.1±7.8 9.4±7.1 0.0037
Duration of HTN(Yrs) 6.67±6.4 6.82±6.4 6.5±6.5 0.320
Waistline (cm) 93.6±11.7 95.1±8.96 94.3±11.4 0.012
SBP (mm Hg) 138.8±18.6 138.1±17.9 139.6±19.2 0.302
DBP (mm Hg) 85.9±10.9 84.7±10.8 85.7±11.0 0.890
FPG (mg/dl) 146.3±62.2 142.9±59.9 149.9±64.5 0.169
PPG (mg/dl) 203.5±80.8 196.2±77.2 210.9±64.5 0.023
HbA1c(%) 7.9±1.9 7.7±1.7 8.1±2.1 0.025
Scr (mg/dl) 1.13±0.7 1.21±0.7 1.05±0.6 <0.001
TCh (mg/dl) 179.1±48.6 174.2±47.6 184.9±48.5 0.001
LDL (mg/dl) 90.9±41.1 87.9±38.7 94.1±43.3 0.079
HDL-C (mg/dl) 58.9±31.4 56.8±29.6 61.2±32.9 <0.001
TG (mg/dl) 157.6±83.1 153.6±88.7 161.9±76.3 0.002
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Patients with macrovascular complications [233 (20 %)],
had the monotherapy prescription in 74 (32 %) and combi-
nation therapy prescription in 159 (68 %). The commonly
prescribed monotherapy, OADs combination, insulin and
OADs combination in patients with macrovascular compli-
cations were insulin 57 (77 %), metformin and sulfonylureas
55 (72 %), insulin metformin and pioglitazone 30 (36 %),
respectively.
Choice of antidiabetic drug therapy and influencing factors
Table 4 shows odds ratio for exploratory variables in logistic
regression for diabetic drug therapy. In this univariate analysis,
family history, diabetes duration, HbA1c, neuropathy, nephrop-
athy, retinopathy, coronary artery disease (CAD) and diabetic
foot complications were all significantly associated with insu-
lin. Patients with the family history of diabetes (OR 1.76, 95 %
Table 2 Patterns of use of anti-diabetic drugs in established T2DM patients
Drug classes N (%) Overall Monotherapy Polytherapy
Overall 2 Drugs 3 Drugs or more
Antidiabetics 1185(100) 348(29) 837(71) 570(48) 267(22)
Insulin 627(53) 214(62) 409(49) 240(42) 169(63)
Metformin 827(70) 81(23) 745(89) 484(85) 261(98)
SUs 520(44) 49(14) 475(49) 319(56) 156(58)
TZD (Pio) 328(28) 4(1) 325(39) 99(17) 226(85)
Percentages of individual drug classes are given within columns: overall, and by number of drugs in regimen
SUs Sulphonylureas, TZD (Pio) Thiazolidinedione pioglitazone
Table 3 Prescribing pattern of anti-diabetic drugs in established T2DM patients with complications
Antidiabetic drugs Overall 1185(100) N (%) Microvascular
complication(s)
Macrovascular
complication(s)
Hyperglycemia
Present Absent Present Absent Controlled Uncontrolled
936 (79) 249 (21) 233 (20) 952 (80) 481 (41) 704 (59)
Monotherapy 348(29) 287(31) 61(24) 74(32) 274(29) 109(23) 239(34)
Insulin 214(62) 176(61) 38(62) 57(77) 157(57) 69(63) 145(61)
Metformin 81(23) 78(27) 3(5) 4(5) 77(28) 19(17) 62(26)
SUs 49(14) 31(11) 18(30) 13(18) 36(13) 20(18) 29(12)
Pioglitazone 4(1) 2(0.7) 2(3) 0(0) 4(1) 1(1) 3(1)
OADs Combination 428(36) 314(34) 114(46) 76(33) 352(37) 212(44) 216(31)
Metformin+SUs 277(65) 207(66) 70(61) 55(72) 222(63) 143(67) 134(62)
Metformin+Pio 24(6) 17(5) 7(6) 3(4) 21(6) 10(5) 14(7)
SUs+Pio 30(7) 19(6) 11(10) 3(4) 27(8) 6(3) 24(11)
Metformin+SUs+Pio 97(23) 71(23) 26(23) 15(20) 82(23) 53(25) 44(20)
Insulin plus OADs 409(35) 335(35) 74(30) 83(35) 326(34) 160(33) 249(35)
Insulin+Metformin 183(45) 151(45) 32(43) 28(34) 155(48) 69(43) 114(46)
Insulin+SUs 12(3) 12(3) 0(0) 1(1) 11(3) 5(3) 7(3)
Insulin+Pio 45(11) 28(8) 17(23) 8(10) 37(11) 13(8) 32(13)
Insulin+Metformin+SUs 40(10) 39(12) 1(1) 14(17) 26(8) 29(18) 11(4)
Insulin+Metformin+Pio 110(27) 92(27) 18(24) 30(36) 80(25) 33(21) 77(31)
Insulin+SUs+Pio 5(1) 3(1) 2(3) 0(0) 5(2) 3(2) 2(1)
Insulin+Metformin+SUs+Pio 14(3) 10(3) 4(5) 2(2) 12(4) 8(5) 6(2)
OAD oral anti-diabetic drugs, SU sulphonylureas, Pio pioglitazone
Percentages are calculated within row for categories in column wise and within categories in each box
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CI 1.18, 2.64), and those with duration of diabetes more than
9 years (OR 2.62, 95 % CI 2.05, 3.36), were more likely to
receive insulin. Patients with BMI >25 kg/m2 were more likely
to receive oral antidiabetic drugs vs. insulin, [metformin (OR
1.25, 95 % CI 1.15, 1.35), sulfonylurea (OR 1.28, 95 % CI
1.01, 1.61)] compared with those having BMI ≤25 kg/m2.
Among controlled vs. uncontrolled BP patients, there were
no differences in prescribing pattern of antidiabetic drugs. The
uncontrolled hyperglycemia and choice of the treatment were
mostly congruous; for example, patients with HbA1c >7 %
were more likely to receive insulin therapy. Patients with post
prandial glucose (PPG) >140 mg/dl were more likely to receive
insulin vs. oral antidiabetic drugs, compared with those
≤140 mg/dl PPG (OR 2.12, 95 % CI, 1.47, 3.10). The odds
ratio of receiving sulfonylurea therapies according to the PPG
>140 mg/dl vs. ≤140 mg/dl was 0.59 (95 % CI 0.40, 0.83).
There were indications of selective prescribing. Patients with
microvascular complications neuropathy, nephropathy and reti-
nopathy were more likely to receive insulin vs. oral antidiabetic
drugs compared with those without neuropathy (OR 1.96, 95 %
CI 1.52, 2.50), nephropathy (OR 1.77, 95 % CI 1.40, 2.24) and
retinopathy (OR 1.97, 95 % CI 1.63, 2.40). Patients with CAD
and diabetic foot were more likely to receive insulin vs. oral
antidiabetic drugs, compared with those with macrovascular
complications CAD (OR 1.57, 95 % CI, 1.14, 2.2) and diabetic
foot (OR 1.62, 95 % CI 1.12, 2.40).
Discussion
We evaluated patterns of antidiabetic drugs prescribed among
established T2DM patients at PGIMER, Chandigarh. Metfor-
min was the most common antidiabetic medication prescribed
in T2DM obese patients. This pattern is consistent with prac-
tice recommendations [18–20]. Post United Kingdom Pro-
spective Diabetes Study (UKPDS) metformin use increased
after 1997 [21–24]. The anti-atherogenic effects of metformin
contributes to reduction in atherothrombotic risk [25], de-
creases weight gain, and is regarded as a useful adjunct in
insulin-requiring patients with type 2 diabetes [26].
Insulin was the most frequently prescribed monotherapy
and also in those with microvascular and macrovascular com-
plications, longer duration of diabetes and general hypergly-
cemia. This is in line with consensus in use of insulin could be
Table 4 Odds ratio for explanatory variables in logistic regression for diabetic drug therapy
Variables Insulin Sulphonylureas Pioglitazone Metformin
OR (95 % CI) P-value OR(95 % CI) P-value OR (95 % CI) P-value OR (95 % CI) P-value
Age (>55 vs. ≤55 years) 1.00 (0.99–1.02) 0.540 1.00 (0.99–1.01) 0.221 0.99 (0.98–1.01) 0.930 0.99 (0.98–1.00) 0.063
Sex (Male vs. Female) 1.04 (0.83–1.31) 0.750 0.80 (0.51–1.37) 0.243 0.94 (0.73–1.22) 0.657 0.68 (0.53–0.87) 0.003
FH (Yes vs. No) 1.76 (1.18–2.64) 0.006 0.03 (0.03–0.04) <0.001 0.75 (0.48–1.17) 0.210 1.10 (0.73–1.67) 0.647
DDM (>9 vs. ≤9 years) 2.62 (2.05–3.36) 0.001 0.54 (0.42–0.69) <0.001 1.17 (0.90–1.50) 0.240 0.87 (0.79–0.96) 0.006
DHTN (>5 vs. ≤5 years) 0.88 (0.69–1.11) 0.275 1.05 (0.83–1.33) 0.711 0.99 (0.76–1.30) 0.950 1.16 (0.90–1.50) 0.255
BMI ( >25 vs. ≤25 kg/m2) 0.79 (0.63–0.99) 0.048 1.28 (1.01–1.61) 0.040 0.99 (0.76–1.28) 0.916 1.25 (1.15–1.35) <0.001
Waistline* 0.96(0.68–1.36) 0.835 1.27(0.90–1.80) 0.172 0.92(0.63–1.35) 0.678 1.67(1.16–2.49) 0.005
SBP ( >130 vs. ≤130 mmHg) 1.10 (0.87–1.4) 0.410 1.04 (0.82–1.32) 0.682 1.05 (0.80–1.36) 0.748 0.99 (0.76–1.30) 0.922
DBP( >80 vs. ≤80 mmHg) 0.99 (0.79–1.25) 0.940 1.07 (0.85–1.36) 0.550 1.07 (0.84–1.38) 0.575 1.02 (0.79–1.30) 0.860
FPG(>110 vs. ≤110 mg/dl) 1.30 (0.90–1.87) 0.149 0.85 (0.57–1.172) 0.269 0.92 (0.63–1.9) 0.272 0.81 (0.54–1.20) 0.549
PPG (>140 vs. ≤140 mg/dl) 2.12 (1.47–3.1) <0.001 0.59 (0.40–0.83) 0.003 0.87 (0.60–1.30) 0.489 0.79 (0.53–1.18) 0.969
HbA1c (>7 vs. ≤7 mg/dl) 1.25 (1.00–1.50) 0.017 0.42(0.30–0.60) <0.001 1.37 (0.94–1.90) 0.105 1.07 (0.74–1.56) 0.700
Neuropathy (yes vs. no) 1.96 (1.52–2.50) 0.035 0.63 (0.49–0.82) <0.001 0.98 (0.74–1.31) 0.921 0.78 (0.51–0.90) 0.008
Nephropathy (yes vs. no) 1.77 (1.40–2.24) <0.001 0.57 (0.45–0.73) <0.001 1.20 (0.95–1.60) 0.115 0.72 (0.56–0.90) 0.01
Retinopathy (yes vs. no) 1.97 (1.63–2.40) <0.001 0.63 (0.52–0.76) <0.001 1.13 (0.93–1.40) 0.214 0.72 (0.60–0.86) <0.001
CAD (yes vs. no) 1.57 (1.14–2.20) 0.034 0.59 (0.43–0.83) 0.002 0.58 (0.39–0.85) 0.006 0.64 (0.46–0.88) 0.007
CVA (yes vs. no) 1.57(0.82–2.9) 0.172 0.45(0.23–0.91) 0.027 0.86(0.42–1.78) 0.16 0.68(0.36–1.29) 0.237
DF (yes vs. no) 1.62(1.12–2.4) 0.01 0.56(0.38–0.83) 0.004 0.65(0.41–1.01)) 0.055 0.51(0.36–0.72) <0.001
Scr(>1.2 vs. ≤1.2 mg/dl) 1.65(1.26–2.16) <0.001 0.58 (0.44–0 .76) <0.001 0.86(0.64–1.16) 0.337 0.44(0.33–0.56) <0.001
*Waist (≤80 vs. >80 cm for male and ≤90 vs. >90 cm for female and sex adjusted odds ratio was calculated)
Odds ratio of >1.1 or <0.9 are in bold
FH family history, DDM duration of diabetes melietus, DHTN duration of hypertension, BMI body mass index, SBP systolic blood pressure, DBP
diastolic blood pressure, FPG fasting plasma glucose, PPG post pradial glucose, HbA1c glycosylated heamoglobin A1C, CAD coronary artery
disease, CVA cerebrovascular accidence, DF diabetic foot, SCr serum creatinin
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justifiable for following evidences; recent meta-analysis
suggesting the benefit of intensive glycemic control by reduc-
tion cardiovascular risk in intensive treatment group [27]. The
studies, The Diabetes Control and Complications Trial -
Epidemiology of Diabetes Interventions and Complications
(DCCT-EDIC) [28] and the UKPDS [29] suggested that in-
tensive glycemic control initiated soon after diagnosis of
diabetes in those with a lower level of CVD risk might impart
long-term protection from CVD events. Long-term follow-up
of the DCCT and UKPDS cohorts suggested that treatment to
A1C targets below or around 7 % in the years soon after the
diagnosis of diabetes was associated with long-term reduction
in macrovascular complications.
About 70 % of T2DM patients were on combination
therapy. Majority of the T2DM patients received two drug
combinations metformin and sulfonylurea or metformin and
insulin. Patients with microvascular and macrovascular
complications were on combination therapy metformin and
sulfonylurea followed by metformin and insulin with the
rationale being to enhance insulin action. Metformin, added
to insulin improved body weight, glycemic control, insulin
requirements, and reduce the risk of macrovascular disease
[30]. Sulfonylurea-metformin combination therapy was as-
sociated with a lower all-cause mortality; cardiovascular
disease related mortality rates were lower in metformin
users, compared with users of sulfonylurea monotherapy
[31]. The treat to target algorithms of recent studies com-
bining OADs plus insulin analogs have demonstrated that
patients can reach glycemic treatment targets with low risk
of hypoglycemia, greater convenience and with some ana-
logs limited weight gain versus conventional insulin. Fur-
ther, in a study of bedtime isophane insulin in combination
with metformin, better glycemic control was achieved with
less weight gain and lower rates of hypoglycemia than either
insulin monotherapy or insulin in combination with sulfo-
nylurea [32]. The use of metformin or glitazones in combi-
nation with insulin has insulin-sparing properties [33].
This pilot study has several limitations also. The choice
of antidiabetic depends on the type of patients, their concur-
rent illness, the potential risks and benefits, the profile of
adverse events, cost factors, as well as the availability of
medicines. The discordance between recommendations and
actual practice can be partially attributed to “clinical iner-
tia,” a phrase used to described as the recognition of a
problem with a patient’s management but failure to act
[34]. The study has not taken into account above variables
for prescribing pattern.
In conclusion, this study finding indicates that medication
use was mostly consistent with evidence based practice guide-
lines in T2DM however, more than half of the patients had
uncontrolled hyperglycemia. There was scope for improve-
ment in prescribing, especially in the T2DM patients with
complications.
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